- Home
- NGG vs REGN Comparison
NGG vs REGN Comparison
Compare NGG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGG | REGN |
|---|---|---|
| Founded | 1990 | 1988 |
| Country | United Kingdom | United States |
| Employees | 31645 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6B | 77.5B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | NGG | REGN |
|---|---|---|
| Price | $87.84 | $753.53 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 3 | 25 |
| Target Price | N/A | ★ $827.76 |
| AVG Volume (30 Days) | ★ 1.1M | 541.7K |
| Earning Date | 05-14-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.47% | 0.50% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 41.48 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | N/A | $12.03 |
| Revenue Next Year | $10.65 | $10.42 |
| P/E Ratio | $115.91 | ★ $18.21 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $67.09 | $476.49 |
| 52 Week High | $94.64 | $821.11 |
Technical Indicators
Market Signals| Indicator | NGG | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 48.36 |
| Support Level | $69.82 | $753.49 |
| Resistance Level | $92.21 | $787.20 |
| Average True Range (ATR) | 1.06 | 17.87 |
| MACD | 0.42 | 0.02 |
| Stochastic Oscillator | 64.86 | 40.54 |
Price Performance
Historical ComparisonAbout NGG National Grid Transco PLC National Grid PLC (NEW)
National Grid owns and operates the electric transmission system in England and Wales. It sold the bulk of its UK gas transmission business in fiscal 2023 to fund the acquisition of PPL's UK power distribution assets. In the Northeastern United States, it serves electricity and gas customers combined in three states. It also owns regulated transmission electricity networks in the United States, metering services and merchant transmission lines in the UK.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).